Home Cart Sign in  
Chemical Structure| 148707-39-5 Chemical Structure| 148707-39-5

Structure of EGCG Octaacetate
CAS No.: 148707-39-5

Chemical Structure| 148707-39-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

EGCG Octaacetate is a precursor of epigallocatechin gallate with anti-inflammatory and antibacterial properties, combating inflammation and cancer by regulating the PI3K/Akt/NFκB signaling pathway.

Synonyms: Peracetylated (-)-epigallocatechin-3-gallate; AcEGCG

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of EGCG Octaacetate

CAS No. :148707-39-5
Formula : C38H34O19
M.W : 794.67
SMILES Code : O=C(O[C@H]1[C@@H](C2=CC(OC(C)=O)=C(OC(C)=O)C(OC(C)=O)=C2)OC3=CC(OC(C)=O)=CC(OC(C)=O)=C3C1)C4=CC(OC(C)=O)=C(OC(C)=O)C(OC(C)=O)=C4
Synonyms :
Peracetylated (-)-epigallocatechin-3-gallate; AcEGCG
MDL No. :MFCD11983067

Safety of EGCG Octaacetate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MRL/lpr mouse mesangial cells 50 μM 1 h EGCG significantly inhibited iNOS protein expression and supernatant NO levels, and reduced IL-6 production. Cell Mol Immunol. 2010 Mar;7(2):123-32.
Naïve CD4+ T cells 10 μM 72 h To evaluate the effect of EGCG on the proliferation of naïve CD4+ T cells. EGCG treatment inhibited the division of naïve CD4+ T cells stimulated with anti-CD3/CD28 antibodies, increasing the proportion of cells arrested in the G0/G1 phase by 8.6% and reducing DNA synthesis activity in the S phase by 51%. Curr Res Food Sci. 2023 Jun 18;7:100537.
Human umbilical vein endothelial cells (HUVECS) 100 µM 60 min EGCG increased NO levels and restored NO levels in PE plasma-treated cells via the PI3K/Akt/eNOS pathway. Antioxidants (Basel). 2024 Jan 26;13(2):158.
Primary human hepatocytes (PHHs) 12.5, 25, and 50 μM 24 h EGCG significantly downregulated HMGB1 secretion and cytoplasmic HMGB1 levels in HBV-infected PHHs Front Immunol. 2023 Apr 14;14:1147379.
HepAD38 cells 12.5, 25, and 50 μM 24 h EGCG significantly downregulated HMGB1 secretion in HBV-replicating hepatoma cells and activated autophagic degradation of cytoplasmic HMGB1 Front Immunol. 2023 Apr 14;14:1147379.
Human bronchial epithelial (HBE) cells 5, 10, 20, 40 µM 24, 48, 72 h EGCG inhibited CSE-induced benzopyrene-DNA adduct formation and modulated miRNA expression profiles. Int J Mol Med. 2021 Dec;48(6):220.
OGD/R-treated HL-1 cells 40 μM 3 h EGCG treatment promoted the viability of OGD/R cells and suppressed LDH levels, with 40 μM EGCG showing the best effects. Chin Med. 2023 Dec 6;18(1):160.
HL-1 cells 0, 5, 10, 20, 40, 80, 100 μM 3 h To evaluate the effect of EGCG on HL-1 cell viability, results showed that EGCG treatment did not exert significant toxicity on HL-1 cells. Chin Med. 2023 Dec 6;18(1):160.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Caenorhabditis elegans Wild-type N2 nematodes Smeared on the surface of agar 200 μM and 1000 μM Survival was recorded every two days from the first day of adulthood until death. To study the alleviating effect of theanine on high-dose EGCG-induced lifespan reduction. Results showed that theanine could alleviate the shortened lifespan induced by high-dose EGCG and improve locomotor ability and body length reduction. Foods. 2021 Jun 17;10(6):1404.
Sprague-Dawley rats Natural aging rats with cognitive impairments Intragastric administration 100 mg/kg Once daily for 4 weeks EGCG significantly ameliorated learning and memory impairments in natural aging rats with CI and decreased Aβ1–42 plaque formation in their brains Acta Pharmacol Sin. 2019 Nov;40(11):1490-1500
Sprague-Dawley rats Lithium-pilocarpine-induced status epilepticus model Intracerebroventricular injection 50 μM Continuous administration EGCG attenuates CA1 neuronal death induced by status epilepticus by regulating GPx1, NF-κB S536 phosphorylation, and mitochondrial dynamics Antioxidants (Basel). 2023 Apr 20;12(4):966
Mice Recombinant cccDNA (rcccDNA) chronic HBV mouse model Intraperitoneal injection 25 mg/kg Daily for 42 consecutive days EGCG treatment significantly alleviated HBV-induced liver injury and fibrosis by autophagic degradation of HMGB1 in hepatocytes and suppression of macrophage NLRP3 inflammasome activation Front Immunol. 2023 Apr 14;14:1147379.
Sprague Dawley rats Cigarette smoke inhalation-induced precancerous bronchial epithelial lesions Drinking water 0.3% EGCG,in drinking water Daily for 16 weeks EGCG significantly reduced cigarette smoke-induced benzopyrene-DNA adduct formation and the development of precancerous bronchial epithelial lesions. Int J Mol Med. 2021 Dec;48(6):220.
C57BL mice Myocardial infarction model Oral gavage 50 mg/kg Once daily for 4 weeks EGCG treatment improved cardiac function in MI mice, reduced myocardial infarction size, and inhibited AIM2 inflammasome-mediated pyroptosis. Chin Med. 2023 Dec 6;18(1):160.
Sprague-Dawley rats Cardiac arrest/cardiopulmonary resuscitation (CA/CPR) model Intravenous injection 3 mg/kg and 9 mg/kg Single dose, observed for 24 hours EGCG dose-dependently alleviated the IRI after CA/CPR, inhibited ERK activity and restored mitochondrial function, as indicated by improved NDS, reduced ROS level, decreased mPTP opening, elevated ATP content, increased ATPase expression and downregulated cleaved-caspase 3 level. Drug Des Devel Ther. 2019 Aug 7;13:2759-2768

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.26mL

0.25mL

0.13mL

6.29mL

1.26mL

0.63mL

12.58mL

2.52mL

1.26mL

 

Historical Records

Categories